SCHEMBL4866296

SCHEMBL4866296

CS(=O)(=O)Nc1ccccc1CN

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PTGS1 P23219 1/20 0.48
NFE2L2 Q16236 1/20 0.47
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 3/20 0.46
RCE1 Q9Y256 1/20 0.46
KMT2A Q03164 1/20 0.45
PTK2 Q05397 1/20 0.45
HPGD P15428 2/20 0.43
EP300 Q09472 1/20 0.43
KAT2B Q92831 1/20 0.43
KAT8 Q9H7Z6 1/20 0.43
GAA P10253 1/20 0.42
NR3C1 P04150 3/20 0.42
PGR P06401 2/20 0.42
NR3C2 P08235 2/20 0.42
AR P10275 2/20 0.42
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15225007 0.98 KEAP1 (0.49) KEAP1L3MBTL1PTGS1NFE2L2ALDH1A1
Acetic Acid SCHEMBL1627791 0.92 KMT2A (0.50) KEAP1L3MBTL1PTGS1ALDH1A1KDM4E
SCHEMBL4861831 0.86 NR3C1 (0.49) KEAP1L3MBTL1PTGS1ALDH1A1KDM4E
SCHEMBL4624724 0.85 KEAP1 (0.47) KEAP1L3MBTL1PTGS1NFE2L2ALDH1A1
SCHEMBL5186762 0.84 PTGS1 (0.62) KEAP1L3MBTL1PTGS1NFE2L2ALDH1A1
SCHEMBL27811591 0.82 KEAP1 (0.52) KEAP1L3MBTL1PTGS1NFE2L2ALDH1A1
SCHEMBL8523655 0.81 KEAP1 (0.44) KEAP1L3MBTL1PTGS1NFE2L2ALDH1A1
SCHEMBL8709063 0.81 KEAP1 (0.50) KEAP1L3MBTL1PTGS1NFE2L2ALDH1A1
SCHEMBL4963565 0.81 KEAP1 (0.55) KEAP1L3MBTL1PTGS1NFE2L2ALDH1A1
SCHEMBL19567904 0.81 KEAP1 (0.50) KEAP1L3MBTL1PTGS1NFE2L2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107428720-B Substituted aminotriazoles as inhibitors of acid mammalian chitinase 昂科艾伦迪治疗法股份公司 2020-06-30 CN disclosed
EP-3233832-B1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS ONCOARENDI THERAPEUTICS SA (PL) 2019-11-20 EP disclosed
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth PFIZER, INC. (US) 2019-10-22 US disclosed
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2019-02-14 US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 US disclosed
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-11-16 US disclosed
EP-3233832-A1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS ONCOARENDI THERAPEUTICS S.A. (PL) 2017-10-25 EP disclosed
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-01-05 US disclosed
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER (US) 2017-01-05 US disclosed
US-20160368894-A1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS OncoArendi Therapeutics Sp. z o.o. (PL) 2016-12-22 US disclosed
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2011-07-07 US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 US disclosed
US-7928109-B2 focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride PFIZER INC (US) 2011-04-19 US disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 US disclosed
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2009-02-26 US disclosed
WO-2008129380-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2008-10-30 WO disclosed
US-7384963-B2 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase GLAXO GROUP LIMITED (GB) 2008-06-10 US disclosed
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-30 US disclosed
EP-1435949-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032986-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450297-B2 Sulfonyl amide derivatives for the treatment of abnormal cell growth GPR119, INSR, LYAR KEAP1 2403/4885L3MBTL1 616/4885PTGS1 2948/4885
US-20170001981-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR KEAP1 2403/4885L3MBTL1 616/4885PTGS1 2948/4885
US-20110166120-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR KEAP1 2403/4885L3MBTL1 616/4885PTGS1 2948/4885
US-20160368894-A1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS ACIDIC MAMMALIAN CHITINASE INHIBITORS CHIA, CHIT1, CMA1 KEAP1 3419/4885L3MBTL1 1880/4885PTGS1 1440/4885
US-20170327485-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR KEAP1 2403/4885L3MBTL1 616/4885PTGS1 2948/4885
US-20190047979-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR KEAP1 2403/4885L3MBTL1 616/4885PTGS1 2948/4885
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors MAPK1, MAPK3, MAPK6 KEAP1 2361/4885L3MBTL1 2010/4885PTGS1 536/4885
US-20090054395-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR KEAP1 2403/4885L3MBTL1 616/4885PTGS1 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.